Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.37 |
| ▸ | WNT1 | P04628 | 7/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914089 | 0.89 | SLC2A1 (0.43) | DYRK1AWNT1GSK3BSLC2A1TLR9 | |
| SCHEMBL4410357 | 0.89 | GSK3B (0.40) | DYRK1AWNT1GSK3BTLR9PDCD1 | |
| SCHEMBL4403763 | 0.83 | TLR9 (0.42) | DYRK1AWNT1GSK3BTLR9PDCD1 | |
| SCHEMBL4396957 | 0.81 | TLR9 (0.42) | DYRK1AWNT1GSK3BTLR9CD274 | |
| SCHEMBL4541737 | 0.81 | SLC2A1 (0.39) | DYRK1AWNT1SLC2A1TLR9TLR8 | |
| SCHEMBL4405858 | 0.81 | PARP1 (0.34) | DYRK1AWNT1TLR9TLR8TLR7 | |
| SCHEMBL4396942 | 0.81 | PARP1 (0.34) | DYRK1AWNT1TLR9TLR8TLR7 | |
| SCHEMBL4410335 | 0.79 | MCHR1 (0.33) | DYRK1ASLC2A1TLR9TLR8TLR7 | |
| SCHEMBL4550682 | 0.79 | GSK3B (0.39) | DYRK1AWNT1GSK3BTLR9CD274 | |
| SCHEMBL4403425 | 0.78 | DYRK1A (0.37) | DYRK1AWNT1SLC2A1TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | claimed |